At OICO we seek out new projects that maximise positive impact on society. We regularly scour the latest scientific works for ideas. Our intention is to convert scientific advances into affordable usable devices in the shortest possible period of time. Narrowing the gap between science and end user diagnostics.
It is within this context that we stumbled upon Advanced Glycation End Products. I won’t go into the details of AGEs (a quick google read up will do a better job than I could). So I’ll jump straight into what we’ve done with AGEs.
AGEs build up in the intra occular (crystaline) lens of the eye over our lifetimes. People at risk of Diabetes (or even Alzheimers) build up more AGEs than “normal” people.
So when measuring the AGE in the crystaline lens and taking into account a patients age, we can estimate whether the person is at high or low risk of developing Diabetes or Alzheimers. AGEs fluorescence at a certain wavelength. SO actually detecting the AGE levels is quite simple with a photon source at wavelength A, and detectors tuned for wavelength B to pick up the fluorescence intensity. There’s no need for any eye drops or tablets as the activation is purely by the wavelength of light.
This method is actually better than blood testing for early stage Diabetes, as blood sugar levels fluctuate, but AGEs are permanent. In addition the test itself takes only a few seconds, allowing a lightly trained domiciliary medical visitor to pre-screen hundreds of people per day using a single device.
Once the patient’s age is entered the device can give a simple answer as to the risk levels of the person’s AGE for Diabetes and potentially Alzheimer’s, before the onset of any symptoms.